Santegoets, Kim C. M.
Gielen, Paul R.
Büll, Christian
Schulte, Barbara M.
Kers-Rebel, Esther D.
Küsters, Benno
Bossman, Sandra A. J. F. H.
ter Laan, Mark
Wesseling, Pieter
Adema, Gosse J.
Funding for this research was provided by:
STOPbraintumors Foundation
European Cooperation in Science and Technology
Radboud Universitair Medisch Centrum
Radboud Institute for Oncology
KWF Kankerbestrijding (KUN2015-7604, KWF11266)
Article History
Received: 14 June 2018
Accepted: 24 March 2019
First Online: 5 April 2019
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
: Experiments were performed in accordance to the Helsinki Declaration and approved by the local Medical Ethics Committee of the Radboudumc (registration number 2011/307).
: Informed consent was obtained from all individual participants included in the study. Patients consented to the use of their blood, tumor material and clinical data for research and publication. The healthy donors also consented to the use of their blood for research and publication.
: Human glioma cell lines U-87 (HTB-14), T98G (CRL-1690) and U-251 were obtained from the American Type Culture Collection (Manassas, VA). The phenotype of these cells was regularly checked; it did not change over time.